These Are The Meteor Showers Not To Miss In 2025 — By An Expert
In 2025, stargazers can look forward to five noteworthy meteor showers, despite some challenges ... More posed by moonlight.
With the peak of the Lyrid meteor shower last night, shooting star season has begun. For stargazers, it's a big deal. Sure, you can see shooting stars any night of the week that comes as a surprise, but that's blind luck. To see them on purpose requires planning.
Major meteor showers tend to come on softly, build to a crescendo on one particular night, and then fade out again. However, many of the major meteor showers in 2025 will be non-events, with strong moonlight rendering all but exceptionally bright shooting stars invisible (for example, August's Perseids will be washed out by an 84%-lit moon).
Here are the five major meteor showers of 2025 to plan for — taking into account the maximum expected rates on peak night and the moon phase — the first of which is about to commence.
Peak night: Monday-Tuesday, May 4-5, 2025
Named after a star in the constellation Aquarius, from which its shooting stars appear to emanate, the Eta Aquarids are caused by Halley's Comet, peaking in the early hours of Monday, May 5. The Southern Hemisphere will have the best views, with up to 60 meteors per hour streaking across the sky, while the Northern Hemisphere will see about half as many. The event will peak at about midnight, but strong moonlight means the best window is about 3:30 a.m. through 5:00 a.m.— set your alarm!
Peak night: Tuesday-Wednesday, July 29-30, 2025
Though less famous than August's Perseids, the Southern Delta Aquariids may offer 2025's best summer meteor display, thanks to a 27%-lit waxing crescent moon that sets shortly after sunset. That leaves midnight to dawn perfectly dark for viewing its expected 15-20 meteors per hour. As a bonus, the same night sees the peak of the Alpha Capricornids, which will add another 5-10 meteors per hour, but with an important twist: they're well known for fireballs — slow, brilliant meteors that can outshine Venus.
385552 01: Halley's Comet in 1986. (Photo by Liaison)
Peak night: Wednesday-Thursday, October 22-23, 2025
The second meteor shower created by Halley's Comet, the Orionids are fast and often leave persistent glowing trails. In 2025, they peak with a waning crescent moon just 2% illuminated, rising well after dawn. This means dark skies all night long, ideal for catching up to 20 meteors per hour.
Peak night: Saturday-Sunday, November 16-17, 2025
The Leonids are famous for occasional meteor storms, though none are predicted in 2025. Still, their meteors are the fastest of any annual shower, streaking in at 160,000 mph (257,000 km/h). A waning crescent moon just 9%-lit will rise during shortly before dawn, but not interfere with the Leonids. Peak viewing will be after midnight, when observers should expect 10–20 meteors per hour — with a few spectacular fireballs possible.
Peak night: Friday-Saturday, December 12-13, 2025
If you only watch one meteor shower in 2025, make it the Geminids. With up to 150 meteors per hour, they're the most prolific of the year, and their bright, slow-moving and even multi-colored meteors make them easy to see — and even photograph. In 2025, a waning crescent moon rising around 2:00 a.m. means dark skies for most of the night, particularly the prime hours between 10 p.m. and 2 a.m. Expect bold fireballs.
Wishing you clear skies and wide eyes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Alcon Inc. (ALC)'s TRYPTYR Wins FDA Nod for Dry Eye Disease
Alcon Inc. (NYSE:ALC) has announced that the U.S. Food and Drug Administration (FDA) has approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye Disease (DED), marking a major milestone for Alcon Inc. (NYSE:ALC) and patients alike. TRYPTYR is the first-in-class TRPM8 receptor agonist eye drop, designed to rapidly stimulate natural tear production by targeting corneal sensory nerves, a novel approach for DED management. A healthcare professional wearing a health communications device discussing patient data with a colleague. In pivotal Phase 3 trials (COMET-2 and COMET-3), TRYPTYR demonstrated a significant increase in natural tear production as early as Day 1, with up to four times more patients achieving at least a 10mm increase in tear production at Day 14 compared to placebo (42.6% vs 8.2% in COMET-2; 53.2% vs 14.4% in COMET-3). These results were consistent through Day 90, highlighting its rapid and sustained efficacy. With nearly 38 million Americans affected by DED but less than 10% receiving prescription treatment, TRYPTYR addresses a critical unmet need, especially given the dissatisfaction and slow onset associated with existing therapies. Alcon Inc. (NYSE:ALC) expects to launch TRYPTYR in the U.S. in the third quarter of 2025. While we acknowledge the potential of ALC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ALC and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
In pivotal Phase 3 trials, TRYPTYR demonstrated rapid natural tear production as early as Day 11-2 TRYPTYR is a first-in-class TRPM8 receptor agonist that rapidly stimulates natural tear production in patients with Dry Eye Disease (DED)3 Approximately 38 million individuals in the U.S. are living with DED, yet less than 10% of diagnosed patients are being treated with a prescription product4 Ad hoc announcement pursuant to Art. 53 LR GENEVA, May 28, 2025--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. Food and Drug Administration (FDA) has approved TRYPTYR® (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease (DED).3 TRYPTYR is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal sensory nerves to rapidly increase natural tear production.3 DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation.5-7 Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence.8-14 Among surveyed dry eye patients, only 13% felt their dry eye was well managed.14* "Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company," said David Endicott, CEO of Alcon. "We look forward to making this new treatment available to millions of patients affected by Dry Eye Disease. We believe TRYPTYR is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy." This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of DED.1-2 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p<0.0001).1-2 Consistent results were observed at all timepoints through Day 90. TRYPTYR demonstrated statistically significant natural tear production as early as Day 1.1-2 "Many of my patients continue to face frustrating challenges with dry eye management, and there is a clear need for additional treatment options," said Marjan Farid, MD, Professor of Ophthalmology at the University of California, Irvine. "TRYPTYR is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of Dry Eye Disease." Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in DED is unknown. TRYPTYR is available in easy-to-use, single dose vials: one drop per eye, two times a day.3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other markets in the future. INDICATIONS AND USAGETRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). IMPORTANT SAFETY INFORMATIONWarnings and PrecautionsPotential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces. Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR. Adverse ReactionsIn clinical trials, the most common adverse reaction was instillation site pain (50%). Please click here for the TRYPTYR Full Prescribing Information. Forward-looking Statements This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "target," "assume," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise. About Dry Eye Dry Eye Disease (DED) is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally.4 While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender.15 Many existing prescription options for DED are generally regarded by many Eye Care Professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability.16 About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at References *Based on an online survey conducted by Chronic Dry Eye from February to April 2021 among 415 responders who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (i.e., levels 3 and 4). Data on File for COMET-2 Phase 3 Study. Alcon 2025. Data on File for COMET-3 Phase 3 Study. Alcon 2025. TRYPTYR® U.S. FDA Prescribing Information. 2025. 2023 Dry Eye Products Markets Report, Market Scope, 2023. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283. doi: 10.1016/ Nattinen J, Aapola U, Nukareddy P, Uusitalo H. Looking deeper into ocular surface health: an introduction to clinical tear proteomics analysis. Acta Ophthalmol. 2022;100:486-498. doi: 10.1111/aos.15059. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510. doi: 10.1016/ Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79. doi: 10.1016/ Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-1094. doi: 10.2147/OPTH.S110557. Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra®) in the U.S. and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041-1054. doi: 10.2147/OPTH.S296510. Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407-420. doi: 10.1007/s40123-019-0188. Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society for Cataract and Refractive Surgery Conference; April 5-6, 2024; Boston, MA. Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings: living with chronic dry eye. ChronicDryEye. August 10, 2021. Accessed September 23, 2024. The Relationship Between Dry Eye Disease and Digital Screen Use - PMC ( Improved Dry Eye Drugs for 2022 and Beyond; Connect with us onFacebook LinkedIn View source version on Contacts Investor Relations Daniel CravensAllen Trang+ 41 589 112 110 (Geneva)+ 1 817 615 2789 (Fort Worth) Media Relations Steven Smith+ 41 589 112 111 (Geneva)+ 1 817 615 2666 (Fort Worth)
Yahoo
19-05-2025
- Yahoo
The moon reaches its half-lit final quarter phase this week: Here's what to expect
When you buy through links on our articles, Future and its syndication partners may earn a commission. Earth's moon reaches its last quarter phase later this week! Read on to discover when and where to catch the fleeting lunar milestone, and what else to find in the nights surrounding May 20. The moon's last quarter - or final quarter phase will occur at 07:59 a.m. EDT (1159 GMT) on the morning of May 20 for viewers in New York, at which point the moon will be visible a little over 30 degrees above the southern horizon, according to The best time to catch the moon in the night sky with close to half its surface lit will be in the pre-dawn hours of May 20, just before it hits the last quarter phase. The following night will see a mere 39% of the moon's disk lit from our perspective on Earth, and the shadowy terminator (the line that separates the lit and unlit portions of the lunar disk) will continue to creep ever further across the lunar surface until it is consumed by shadow during the new moon phase on May 26. On May 20 the lunar disk will be bisected by the terminator, with the left half illuminated by the sun, and the right drenched in shadow, throwing several large craters into relief. One of these, Tycho crater, will make for an excellent telescope target at this time, as a lip of the 53-mile-wide (85 km) distinctive central impact peak casts strong shadows over the interior of the depression. It's relatively easy to spot as the largest crater in the moon's rugged southern highlands close to the bottom of the lunar disk. The 57-mile-wide (93 km) Copernicus Crater will also be easily visible on the nights surrounding May 20 a little left of the terminator, close to the lunar equator. Meanwhile the darker expanses of Oceanus Procellarum (Ocean of Storms) and the surrounding lunar maria (which is Latin for seas) will dominate the north west of the moon's tidally locked disk, according to NASA. These relatively unscarred swaths of lunar terrain were created billions of years ago when masses of lava flooded impact basins created during a period of intense bombardment from asteroids, comets and other smaller solar system bodies. The lava flows eventually cooled to form enormous basaltic plains that are now visible to the naked eye from the surface of our planet. Earth's moon will be accompanied in the southeastern sky by stars from the constellation Aquarius on the left, and Capricornus on the right, when it slips above the horizon at 1:55 a.m. EDT (0555 GMT) on the morning of May 20 for skywatchers in New York. Be sure to check out a trusted website like to find out the exact time for moonrise in your location. TOP TELESCOPE PICK: Want to explore Tycho Crater and the southern lunar highlands for yourself? The Celestron NexStar 4SE is ideal for beginners wanting quality, reliable and quick views of celestial objects. For a more in-depth look at our Celestron NexStar 4SE review. The bright stars Altair and Vega will be visible twinkling above the moon, while the planets Saturn and Venus will become visible climbing ever higher into the eastern sky to the left of the moon in the hour preceding sunrise. Stargazers hoping to explore the lunar surface with a little extra magnification should read our guides on the best binocular and telescope deals available in 2025. Photographers hoping to catch a glimpse of the solar system at play would also do well to check out our roundup of the best cameras and lenses for astrophotography. Want to take your own photos of the lunar surface? Check out our guide on how to photograph the moon. Editor's Note: If you capture a photo of the third quarter moon and would like to share it with readers, then send your photo(s), comments, and your name and location to spacephotos@
